Armata Pharmaceuticals, Inc.
AP-SA02
complicated S. aureus bacteremia
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on AP-SA02 for complicated S. aureus bacteremia is in focus around Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“If successful, AP-SA02 has the potential to offer an important new treatment option for patients facing this serious and often life-threatening infection.”